John D. Merriman

John D. Merriman

Auto-generated profile, based on publicly available information

John D. Merriman

University of Pittsburgh

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2014 in Biological Research For Nursing
Verified
Journal Article
Closed access
SDSy-Huey Doong
Sy-Huey Doong
ADAnand Dhruva
Anand Dhruva
LDLaura B. Dunn
Laura B. Dunn
CWClaudia West
Claudia West
SPSteven M. Paul
Steven M. Paul
CMChristine Miaskowski
Christine Miaskowski
Pain, fatigue, sleep disturbance, and depression are common and frequently co-occurring symptoms in oncology patients. This symptom cluster is often attributed to the release of proinflammatory cytokines. The purposes of this study were to determine whether distinct latent classes of patients with breast cancer ( n = 398) could be identified based on their experience with this symptom cluster, whether patients in these latent classes differed on demographic and clinical characteristics and whether variations in cytokine genes were associated with latent class membership. Three distinct latent classes were identified: “all low” (61.0%), “low pain and high fatigue” (31.6%), “all high” (7.1%). Compared to patients in the all low class, patients in the all high class were significantly younger, had less education, were more likely to be non-White, had a lower annual income, were more likely to live alone, had a lower functional status, had a higher comorbidity score, and had more advanced disease. Significant associations were found between interleukin 6 (IL6) rs2069845, IL13 rs1295686, and tumor necrosis factor alpha rs18800610 and latent class membership. Findings suggest that variations in pro- and anti-inflammatory cytokine genes are associated with this symptom cluster in breast cancer patients.

1 December 2012 in The Journal of Pain
Verified
Journal Article
Closed access
CMChristine Miaskowski
Christine Miaskowski
BCBruce Cooper
Bruce Cooper
SPSteven M. Paul
Steven M. Paul
CWClaudia West
Claudia West
DLDale Langford
Dale Langford
BABradley E. Aouizerat
Bradley E. Aouizerat

23 April 2015 in Cancer
Verified
Journal Article
Open access
PDF file
CBCatherine M. Bender
Catherine M. Bender
JMJohn D. Merriman
John D. Merriman
AGAmanda L. Gentry
Amanda L. Gentry
GAGretchen M. Ahrendt
Gretchen M. Ahrendt
SBSarah L. Berga
Sarah L. Berga
SSSusan M. Sereika
Susan M. Sereika
BACKGROUND: The purpose of this study was to examine and compare the effects of the first 18 months of anastrozole therapy on cognitive function in women with breast cancer.METHODS: This large, longitudinal cohort study was composed of postmenopausal women with early‐stage breast cancer who received chemotherapy plus anastrozole (n = 114) or anastrozole alone (n = 173) and a control group (n = 110). Cognitive function was assessed before systemic therapy and 6, 12, and 18 months after therapy initiation and at comparable time points in controls.RESULTS: The chemotherapy‐anastrozole and anastrozole‐alone groups had poorer executive function than the controls at nearly all time points (P < .0001 to P = .09). A pattern of deterioration in working memory and concentration was observed during the first 6 months of anastrozole therapy for the chemotherapy‐anastrozole group (P < .0001 and P < .0009, respectively) and the anastrozole‐alone group (P = .0008 and P = .0002, respectively). This was followed by improved working memory and concentration from 6 to 12 months in both groups. The anastrozole‐alone group had a second decline in working memory and concentration from 12 to 18 months after the initiation of therapy (P < .0001 and P = .02, respectively).CONCLUSIONS: Women with breast cancer had poorer executive functioning from the period before therapy through the entire first 18 months of therapy. A pattern of decline in working memory and concentration with initial exposure to anastrozole was observed. Women receiving anastrozole alone had a second deterioration in working memory and concentration from 12 to 18 months after therapy initiation. The longer term effects (>18 months) of anastrozole on cognitive function remain to be determined. Cancer 2015;121:2627–2636. © 2015 American Cancer Society.

3 January 2013 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JCJanine K Cataldo
Janine K Cataldo
SPSteven Paul
Steven Paul
BCBruce Cooper
Bruce Cooper
HSHelen Skerman
Helen Skerman
KAKim E. Alexander
Kim E. Alexander
CMChristine Miaskowski
Christine Miaskowski
Background: Mortality rates for cancer are decreasing in patients under 60 and increasing in those over 60 years of age. The reasons for these differences in mortality rates remain poorly understood. One explanation may be that older patients received substandard treatment because of concerns about adverse effects. Given the paucity of research on the multiple dimensions of the symptom experience in older oncology patients, the purpose of this study was to evaluate for differences in ratings of symptom occurrence, severity, frequency, and distress between younger (< 60 years) and older ( ≥ 60 years) adults undergoing cancer treatment. We hypothesized that older patients would have significantly lower ratings on four symptom dimensions. Methods: Data from two studies in the United States and one study in Australia were combined to conduct this analysis. All three studies used the MSAS to evaluate the occurrence, severity, frequency, and distress of 32 symptoms. Results: Data from 593 oncology outpatients receiving active treatment for their cancer (i.e., 44.4% were < 60 years and 55.6% were ≥ 60 years of age) were evaluated. Of the 32 MSAS symptoms, after controlling for significant covariates, older patients reported significantly lower occurrence rates for 15 (46.9%) symptoms, lower severity ratings for 6 (18.9%) symptoms, lower frequency ratings for 4 (12.5%) symptoms, and lower distress ratings for 14 (43.8%) symptoms. Conclusions: This study is the first to evaluate for differences in multiple dimensions of symptom experience in older oncology patients. For almost 50% of the MSAS symptoms, older patients reported significantly lower occurrence rates. While fewer age-related differences were found in ratings of symptom severity, frequency, and distress, a similar pattern was found across all three dimensions. Future research needs to focus on a detailed evaluation of patient and clinical characteristics (i.e., type and dose of treatment) that explain the differences in symptom experience identified in this study.

1 June 2014 in European Journal of Oncology Nursing
Verified
Journal Article
Closed access
CMChristine Miaskowski
Christine Miaskowski
SPSteven M. Paul
Steven M. Paul
BCBruce Cooper
Bruce Cooper
CWClaudia West
Claudia West
JLJon D. Levine
Jon D. Levine
BABradley E. Aouizerat
Bradley E. Aouizerat

1 March 2014 in Lymphatic Research and Biology
Verified
Journal Article
Closed access
GLGeraldine Leung
Geraldine Leung
CBChristina Baggott
Christina Baggott
CWClaudia West
Claudia West
CECharles Elboim
Charles Elboim
SPSteven M. Paul
Steven M. Paul
CMChristine Miaskowski
Christine Miaskowski
Background: Lymphedema (LE) is a frequent complication following breast cancer treatment. While progress is being made in the identification of phenotypic risk factors for the development of LE, little information is available on the molecular characterization of LE. The purpose of this study was to determine if variations in pro- and anti-inflammatory cytokine genes were associated with LE following breast cancer treatment. Methods and Results: Breast cancer patients completed a number of self-report questionnaires. LE was evaluated using bioimpedance spectroscopy. Genotyping was done using a custom genotyping array. No differences were found between patients with (n=155) and without LE (n=387) for the majority of the demographic and clinical characteristics. Patients with LE had a significantly higher body mass index, more advanced disease, and a higher number of lymph nodes removed. Genetic associations were identified for three genes (i.e., interleukin (IL4) 4 (rs2227284), IL 10 (rs1518111), and nuclear kappa factor beta 2 (NFKB2 (rs1056890)) associated with inflammatory responses. Conclusions: These genetic associations suggest a role for a number of pro- and anti-inflammatory genes in the development of LE following breast cancer treatment.